thyroid cancer
Veracyte Eyes Dropping IVD/Pharma Subsidiary in Europe As Growth Concentrates Among Clinical LDTs
Premium
Company officials lauded its core tests and shared news about launches planned for the upcoming year, including its minimal residual disease assay.
UBS Initiates Coverage of Veracyte With Buy Rating
Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.
Veracyte Q2 Revenues up 27 Percent on Prostate, Thyroid Tests; Firm Raises Full-Year Guidance
The company said that it set records for test volume for both its Decipher Prostate test and Afirma assay for thyroid nodule risk stratification.
Veracyte Core Tests Maintain Growth as Firm Prepares to Shift Resources to Newest Acquisitions
Premium
The company is anticipating that its new MRD platform, acquired earlier this year, will be fuel for significant future development and expansion.
Veracyte Q4 Revenues Grow 22 Percent, Topping Estimates
Veracyte reported Q4 revenues of $98.2 million driven by strong sales of its Afirma thyroid cancer and Decipher prostate cancer tests.
Jan 31, 2020
Dec 20, 2019